TCG Crossover Management, LLC

Position in FULC — Fulcrum Therapeutics, Inc.

CIK 1839948 PALO ALTO, CA

Position in FULC

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$40,267,500

-$19,110,000 QoQ

Shares Held

5,250,000

0.0% QoQ

Ownership

7.88%

of shares outstanding

% of Portfolio

1.15%

of 13F equity value

Holder Rank

of 168 holders

Holding Since

Sep 2024

7 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

TCG Crossover Management, LLC holds $3,218,747,876 across 44 Biotechnology names. FULC ranks #21 (1.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ABVX	Abivax S.A.	6,481,085	$721,668,814
2	CGON	CG Oncology, Inc.	3,670,206	$248,399,542
3	TNGX	Tango Therapeutics, Inc.	10,531,071	$220,310,005
4	COGT	Cogent Biosciences, Inc.	4,946,894	$190,405,950
5	CNTA	Centessa Pharmaceuticals plc	4,286,480	$170,258,985
6	DNTH	Dianthus Therapeutics, Inc. /DE/	1,676,624	$140,702,286
7	TYRA	Tyra Biosciences, Inc.	3,248,980	$124,435,934
8	IMVT	Immunovant, Inc.	4,457,988	$110,736,421

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$40,267,500	5,250,000	0.0%	Shares	Sole	2026-05-15
2025-12-31	$59,377,500	5,250,000	0.0%	Shares	Sole	2026-02-17
2025-09-30	$48,300,000	5,250,000	0.0%	Shares	Sole	2025-11-17
2025-06-30	$36,120,000	5,250,000	0.0%	Shares	Sole	2025-08-14
2025-03-31	$15,120,000	5,250,000	0.0%	Shares	Sole	2025-05-14
2024-12-31	$24,675,000	5,250,000	0.0%	Shares	Sole	2025-02-14
2024-09-30	$18,742,500	5,250,000	—	Shares	Sole	2024-11-14
No filing history on record for this holder in this stock.